INGN 225

Drug Profile

INGN 225

Alternative Names: Ad.p53 DC vaccine; Adenovirus-p53 transduced dendritic cell vaccine; Autologous dendritic cell adenovirus p53 vaccine; P53 immunotherapy

Latest Information Update: 03 Jan 2017

Price : $50

At a glance

  • Originator H. Lee Moffitt Cancer Center and Research Institute; Vanderbilt-Ingram Cancer Center
  • Developer H. Lee Moffitt Cancer Center and Research Institute; NewLink Genetics Corporation; University of Nebraska Medical Center
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants; P53 gene stimulants; Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Breast cancer; Small cell lung cancer

Most Recent Events

  • 03 Jan 2017 INGN 225 is still in phase II trials for Small cell lung cancer in USA (NCT00617409)
  • 03 Jun 2013 Phase-II clinical trials in Breast cancer (Combination therapy) in USA (SC)
  • 14 May 2013 Phase-I/II clinical trials in Breast cancer in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top